Ryohei Katayama

List of Publications by Year in Descending Order

61 papers	8,846 citations	35 h-index	64 g-index
64 ext. papers	10,191 ext. citations	10.7 avg, IF	5.53 L-index

#	Paper	IF	Citations
61	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. *Npj Precision Oncology*, **2022**, 6, 5	9.8	0
60	GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.. *Npj Precision Oncology*, **2022**, 6, 16	9.8	1
59	Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. *Cancer Science*, **2021**, 112, 2299-2313	6.9	3
58	Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. *Npj Precision Oncology*, **2021**, 5, 32	9.8	6
57	Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. *Cancer Science*, **2021**, 112, 2371-2380	6.9	5
56	A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. *Respiratory Medicine Case Reports*, **2021**, 33, 101405	1.2	2
55	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. *Nature Communications*, **2021**, 12, 1261	17.4	14
54	Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. *Oncogene*, **2021**, 40, 5548-5558	9.2	2
53	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 4785-4794	12.9	29
52	Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method. *Scientific Reports*, **2020**, 10, 2161	4.9	4
51	Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. *Cancer Science*, **2020**, 111, 932-939	6.9	20
50	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. *Journal of Thoracic Oncology*, **2020**, 15, 752-765	8.9	12
49	Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. *Thoracic Cancer*, **2020**, 11, 581-587	3.2	11
48	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. *Cancer Chemotherapy and Pharmacology*, **2020**, 86, 517-525	3.5	2
47	Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. *EBioMedicine*, **2019**, 41, 105-119	8.8	60
46	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. *Journal of Experimental Medicine*, **2019**, 216, 982-1000	16.6	105
45	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of Mutation Status. *Cancer Research*, **2019**, 79, 1658-1670	10.1	44

44	The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. *Nature Communications*, **2019**, 10, 3604	17.4	65
43	Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. *Cancer Science*, **2018**, 109, 572-580	8.9	39
42	High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. *Lung Cancer*, **2018**, 117, 1-6	5.9	34
41	A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (). *Oncotarget*, **2018**, 9, 33322-33336	3.3	4
40	Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. *Oncotarget*, **2018**, 9, 1641-1655	3.3	16
39	3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. *Biochemical and Biophysical Research Communications*, **2018**, 501, 527-533	3.4	3
38	Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. *Journal of Thoracic Oncology*, **2018**, 13, 915-925	8.9	15
37	Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. *Leukemia*, **2018**, 32, 2590-2603	10.7	36
36	Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 752-762	6.1	52
35	Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. *Pharmacology & Therapeutics*, **2017**, 177, 1-8	13.9	21
34	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. *Nature Communications*, **2017**, 8, 14768	17.4	197
33	Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 2130-2143	6.1	60
32	TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity. *Scientific Reports*, **2017**, 7, 5519	4.9	7
31	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. *Cancer Discovery*, **2016**, 6, 1118-1133	24.4	648
30	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. *EBioMedicine*, **2016**, 3, 54-66	8.8	97
29	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. *New England Journal of Medicine*, **2016**, 374, 54-61	59.2	334
28	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. *Cancer Cell*, **2015**, 28, 70-81	24.3	301
27	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. *Nature Communications*, **2015**, 6, 6377	17.4	358

26	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. *Clinical Cancer Research*, **2015**, 21, 166-74	12.9	145
25	Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. *Clinical Cancer Research*, **2015**, 21, 2227-35	12.9	188
24	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. *Cancer Discovery*, **2014**, 4, 662-673	24.4	591
23	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. *Science*, **2014**, 346, 1480-6	33.3	507
22	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. *Clinical Cancer Research*, **2014**, 20, 5686-96	12.9	227
21	Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. *Molecular Cancer Therapeutics*, **2014**, 13, 2978-90	6.1	46
20	Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. *Cancer Research*, **2013**, 73, 3087-96	10.1	164
19	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 4273-81	12.9	411
18	Acquired resistance to crizotinib from a mutation in CD74-ROS1. *New England Journal of Medicine*, **2013**, 368, 2395-401	59.2	268
17	ROS1 rearrangements define a unique molecular class of lung cancers. *Journal of Clinical Oncology*, **2012**, 30, 863-70	2.2	1170
16	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Science Translational Medicine*, **2012**, 4, 120ra17	17.5	948
15	Transforming growth factor-□decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. *Oncogene*, **2011**, 30, 1693-705	9.2	66
14	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7535-40	11.5	445
13	Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. *Journal of Biological Chemistry*, **2011**, 286, 2681-8	5.4	24
12	Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L. *Journal of Cell Science*, **2010**, 123, 23-8	5.3	22
11	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. *Journal of Clinical Oncology*, **2010**, 28, 4953-60	2.2	296
10	AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. *Oncology Research*, **2010**, 19, 23-33	4.8	53
9	Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. *Cancer Science*, **2009**, 100, 2060-8	6.9	62

8	TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling. *Cancer Science*, **2008**, 99, 1827-34	6.9	24
7	Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. *Cancer Research*, **2008**, 68, 5076-85	10.1	217
6	Impairment of the ubiquitin-proteasome system by cellular FLIP. *Genes To Cells*, **2007**, 12, 735-44	2.3	18
5	Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. *Cancer Research*, **2007**, 67, 9666-76	10.1	53
4	Cell differentiation inducers derived from thalidomide. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3212-5	2.9	11
3	Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling. *Molecular and Cellular Biology*, **2004**, 24, 8418-27	4.8	39
2	Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. *Nature Cell Biology*, **2004**, 6, 849-60	23.4	187
1	Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments. *FEBS Letters*, **2002**, 520, 117-21	3.8	56